Lilly gains again in US court on NFkappaB patent suit with Ariad
This article was originally published in Scrip
Executive Summary
Lilly has scored another victory in the case of Ariad Pharmaceuticals et al v Lilly, relating to whether certain claims of Ariad's US patent No 6,410,516 (the '516 patent) covering a chemical pathway are infringed by two of Lilly's drugs, Evista (raloxifene) and Xigris (drotrecogin alfa).